Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
ArriVent BioPharma, Inc. (AVBP) had Normalized Income after Taxes of $-34.98M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-34.98M |
|
-- |
|
-- |
|
$38.32M |
|
$-38.32M |
|
$3.34M |
|
$-34.98M |
|
$-34.98M |
|
$-34.98M |
|
$-34.98M |
|
$-34.98M |
|
|
Normalized Income after Taxes |
$-34.98M |
$-38.32M |
|
$-38.32M |
|
41.91M |
|
41.91M |
|
$-0.83 |
|
$-0.83 |
|
| Balance Sheet Financials | |
$321.22M |
|
-- |
|
$5.34M |
|
$326.56M |
|
$21.56M |
|
-- |
|
-- |
|
$21.56M |
|
$305.00M |
|
$305.00M |
|
$305.00M |
|
40.85M |
|
| Cash Flow Statement Financials | |
$-129.93M |
|
$-0.03M |
|
$168.34M |
|
$74.29M |
|
$112.67M |
|
$38.38M |
|
$9.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.90 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-129.93M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.47% |
|
-11.47% |
|
-10.71% |
|
-11.47% |
|
$7.47 |
|
$-3.10 |
|
$-3.10 |
|